GLP1R and type 2 diabetes mellitus: A clinically validated pathway for T2D therapy is modulation of the incretin hormone glucagon-like peptide-1 (GLP-1), which acts on GLP-1 receptor in pancreatic islets to promote glucose-dependent insulin secretion, thus reducing glucose without causing hypoglycemia.